Research Director, UCLA Cannabis Research Initiative; Associate Professor of Psychiatry
University of California, Los Angeles · Los Angeles, CA
Ziva Cooper directs the UCLA Cannabis Research Initiative, one of the largest academic cannabis research programs in the United States. Her laboratory conducts human laboratory studies and clinical trials examining the pharmacology, therapeutic potential, and risks of cannabis and cannabinoids. Cooper has particular expertise in the intersection of cannabis and pain — her research has shown that CBD can enhance the analgesic effects of low-dose THC while reducing its adverse effects, providing a mechanistic basis for balanced THC:CBD formulations. She has also conducted important research on cannabis and opioid interactions, demonstrating that cannabis can reduce opioid consumption in chronic pain patients. Cooper is a frequent advisor to the FDA, DEA, and state cannabis regulatory agencies.
Neuropsychopharmacology · 2020
Human laboratory study showing CBD (400mg oral) significantly reduced THC-induced paranoia and working memory impairment without reducing THC analgesia. Provides mechanistic support for balanced THC:CBD formulations in clinical use.
DOI: 10.1038/s41386-020-0706-xJournal of Pain · 2018
Controlled human laboratory study demonstrating that vaporized cannabis (THC 5.6%) significantly reduced opioid self-administration in chronic pain patients by 27% vs. placebo. Provides controlled evidence for cannabis-opioid interactions relevant to the opioid crisis.
DOI: 10.1016/j.jpain.2018.01.009Drug and Alcohol Dependence · 2016
Human laboratory study finding women showed greater analgesic response to THC than men at equivalent doses, but also greater anxiety and cognitive impairment. Established sex as a critical variable in cannabis pharmacology research and clinical dosing.
DOI: 10.1016/j.drugalcdep.2016.01.021